Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2001

View Archived Issues

Pharmacological interaction of irofulven and docetaxel under study

Additional MS-325 phase II clinical trial results presented this week

IND opened for the TranStem stem cell expansion system

Bayer worldwide licensing offer

Second orphan drug designation received for orBec in GVHD

First trial of thioredoxin inhibitor initiated in cancer patients

Potent new p38 MAP kinase inhibitor suppresses cytokine release, skin inflammation

Preclinical profile of ML-3000, a new COX/5-LO inhibitor, discussed at Inflammation 2001

UR-8880 exerts potent antiinflammatory effects in the absence of GI toxicity

ABT-627 beneficial in newborn lambs with congenital diaphragmatic hernia and pulmonary hypertension

Surfaxin not associated with changes in fetal human pulmonary cell physiology

Potential therapy for GVHD continues in late-stage clinical development

Irbesartan gives renal protection in type 2 diabetes patients independent of blood pressure effect

Alzheimer's Disease Cooperative Study receives research award from NIA

First IND filed for product emerging from Lilly/Ligand metabolic disease collaboration

Enrollment completed for phase IIa trial of repifermin for mucositis

Development candidate selected by GSK from Cytokinetics' second-generation antimitotics

Phase II trial assessing Angiozyme in combination with chemotherapy initiated

InterMune acquires worldwide rights to oritavancin from Lilly

Inflazyme initiates two trials to study novel antiinflammatory compounds

Genaera receives Cystic Fibrosis Foundation grant to develop Lomucin

Lundbeck presents several classes of 5-HT1A receptor ligands

HIV reverse transcriptase inhibitors described by Pfizer team

Recent U.S. patent covers new sulfonamides and use for atherosclerosis, restenosis

Phosphonic acid-based inhibitors of FBPase synthesized at Metabasis

Inhibitors of cytokine production under development by Hokuriku Seiyaku

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...